See updated messages from the NIDA HRP scientific leadership team.
Funding Opportunities of Note
- NIDA Avant-Garde Program for HIV and Substance Use Disorder Research (DP1 Clinical Trial Optional) PAR-25-261
- A new funding opportunity to break down barriers impeding the use of PrEP among people who use substances:
- Research to Address Systemic and Structural Barriers and Facilitators to Improve the HIV Pre-Exposure Prophylaxis (PrEP) Care Continuum for People Who Use Substances (R01 Clinical Trials Required) RFA-DA-26-003
- Research to Address Systemic and Structural Barriers and Facilitators to Improve the HIV Pre-Exposure Prophylaxis (PrEP) Care Continuum for People Who Use Substances (R34 Clinical Trials Required) RFA-DA-26-004
- Avenir Award Program for Research on Substance Use Disorders and HIV (DP2 Clinical Trial Optional) PAR-23-125
- Notice of Clarification for PAR-23-269 and PAR-23-125 - NOT-DA-24-034
- High Priority HIV and Substance Use Research (R01 Clinical Trial Optional) RFA-DA-25-024
- High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional) RFA-DA-25-060
- AIDS-Science Track Award for Research Transition (R03 Clinical Trial Optional) PAS-21-270
- Notice of Special Interest (NOSI): Research to Address Ending the HIV Epidemic Initiative Goals Relevant to Substance Using Populations At-Risk for or Living with HIV, NOT-DA-23-013
Basic Research
- Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed) RFA-DA-25-069
- Targeting Inflammasomes in HIV and Substance Use (R21 Clinical Trial Not Allowed) RFA-DA-25-068
- Mitochondrial-associated Mechanisms of Neuropathological and Immunodeficient Aging in the Context of HIV and SUD (R01 Clinical Trials Not Allowed) RFA-DA-26-009
- Mitochondrial-associated Mechanisms of Neuropathological and Immunodeficient Aging in the Context of HIV and SUD (R21 Clinical Trials Not Allowed) RFA-DA-26-010
- Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R34 Clinical Trial Optional) RFA-25-070
- Accelerating the Pace of Substance Use Research Using Existing Data (R21 Clinical Trial Not Allowed) RFA-DA-26-056
- Accelerating the Pace of Substance Use Research Using Existing Data (R01 Clinical Trial Not Allowed) RFA-DA-26-055
- HIV Prevention and Alcohol (R01 Clinical Trials Optional) PAS-25-208
- HIV Prevention and Alcohol (R34 Clinical Trials Optional) PAS-25-161
- Advancing Research on Molecular Targets and Mechanisms that Influence the Interplay Between Sex Hormones, HIV, and Addictive Substances (R01 Clinical Trials Not Allowed) RFA-DA-26-007
- Advancing Research on Molecular Targets and Mechanisms that Influence the Interplay Between Sex Hormones, HIV, and Addictive Substances (R21 Clinical Trials Not Allowed) RFA-DA-26-008
- Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Data Mining and Functional Validation (R21 Clinical Trial Not Allowed) RFA-DA-26-002
- Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Data Mining and Functional Validation (R01 Clinical Trial Not Allowed) RFA-DA-26-001
- Microglial Pathophysiology in Comorbid Substance Use Disorder (SUD) and HIV (R61/R33 Clinical Trial Not Allowed) RFA-DA-25-063
- Exploratory Studies to Investigate Mechanisms of HIV infection, Replication, Latency, and/or Pathogenesis in the Context of Substance Use Disorders (R01 Clinical Trial Not Allowed) RFA-DA-25-073
- Notice of Special Interest (NOSI): Advancing HIV/AIDS Research through Computational Neuroscience. NOT-DA-21-030
- Ex Vivo Models for Studies at the Intersection of HIV and Poly-Substance Use (R01 Clinical Trial Not Allowed) RFA-DA-24-001
Clinical, Epidemiological, and Implementation Science Research
- Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R34 Clinical Trial Optional) RFA-DA-25-070
- Accelerating the Pace of Substance Use Research Using Existing Data (R21 Clinical Trial Not Allowed) RFA-DA-26-056
- Behavioral and Integrative Treatment Development Program (R01 Clinical Trial Optional). PAR-24-299
- Behavioral and Integrative Treatment Development Program (R34 Clinical Trial Optional). PAR-24-300
- Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Not Allowed) PAR-25-134
- Role of Defective Proviruses in HIV Persistence (R01 Clinical Trial Not Allowed) PAR-25-330
- Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R34 Clinical Trial Optional) PAR-25-100
- Interventions to Address Disparities in Liver Diseases and Liver Cancer (R01 - Clinical Trials Optional) PAR-25-299
- Mobile Health: Technology and Outcomes in Low and Middle Income Countries (R21/R33 - Clinical Trial Optional) PAR-25-242
- Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional) PAR-24-298
- Notice of Participation of NIDA in RFA-MH-25-186, "Advancing HIV service delivery through pharmacies and pharmacists (R21 Clinical Trial Optional)" NOT-DA-24-033
- Notice of Change to Application Due Date for PA-21-205, "Development & Testing of Novel Interventions to improve HIV Prevention, Treatment, and Program Implementation for People Who Use Drugs (R34 Clinical Trial Required)" NOT-DA-24-023
- Notice of Special Interest (NOSI): Saving Lives: Integrating Overdose Education and Naloxone Distribution (OEND) into HIV Prevention and Care Settings for People Who Use Addictive Substances NOT-DA-25-031
- Development & Testing of Novel Interventions to improve HIV Prevention, Treatment, and Program Implementation for People Who Use Drugs (R34 Clinical Trial Required) PA-21-205
- Stimulants and HIV: Addressing Contemporary and Recurring Epidemics (R61/R33 - Clinical Trial Required). RFA-DA-23-008
- Notice of NIDA Participation in NOT-MH-21-105, "Notice of Special Interest: Advancing Health Communication Research on HIV Prevention, Treatment and Cure"
- Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R34 - Clinical Trial Optional) PA-21-180
Medical Consequences and Cross-Cutting Research
- Notice of Special Interest (NOSI): Pharmacogenomic Approaches to Enhancing HIV and Substance Use Disorder (SUD) Treatment Strategies, A jump into Precision Medicine – NOT-DA-24-001
- Notice of Special Interest (NOSI): Chemsex and HIV: prevalence, medical/psychosocial consequences, and treatment, NOT-DA-24-002
Program Projects and Center Grants
- NIDA Program Project Grant Applications (P01 Clinical Trial Optional). PAR-23-064
- NIDA Research Center of Excellence Grant Program (P50 Clinical Trial Optional) PAR-23-076
- NIDA Core "Center of Excellence" Grant Program (P30 Clinical Trial Optional) PAR-23-049
Career Development and NRSA Fellowship Grants
- NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional) PAR-24-089
- NIDA Training and Career Development Fellowships & Grants